Discovery of novel selective inhibitors for EGFR-T790M/L858R

  • Fang Bai
  • , Hongyan Liu
  • , Linjiang Tong
  • , Wei Zhou
  • , Li Liu
  • , Zhenjiang Zhao
  • , Xiaofeng Liu
  • , Hualiang Jiang
  • , Xicheng Wang*
  • , Hua Xie
  • , Honglin Li
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Through a receptor-based and ligand-based combined virtual screening protocol, 21 novel compounds covering 15 scaffolds were identified as novel inhibitors for EGFR-T790M/L858R, among which, 12 of them were identified as selective inhibitors for EGFR-T790M/L858R to wild-type EGFR, and 5 of them exhibited 'dual-effective' to wild-type and mutant EGFR. Meanwhile, their antiproliferative effects toward EGFR high-expressing human lung cancer cell (A549), epidermoid carcinoma cell (A431), and the mutant EGFR-dependent cell (NCI-H1975) were also evaluated.

Original languageEnglish
Pages (from-to)1365-1370
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume22
Issue number3
DOIs
StatePublished - 1 Feb 2012
Externally publishedYes

Keywords

  • Dual-effective inhibitors
  • EGFR
  • Kinase inhibitors
  • Selective inhibitors
  • T790M/L858R
  • Virtual screening

Fingerprint

Dive into the research topics of 'Discovery of novel selective inhibitors for EGFR-T790M/L858R'. Together they form a unique fingerprint.

Cite this